dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Riigieelarve eraldise kasutamise lepingAvalik

Leping

Sotsiaalministeerium · 4. august 2020
Viit
3-4/1165-1
Registreeritud
4. august 2020
Dokumendi liik
Riigieelarve eraldise kasutamise leping
Funktsioon
3 Sihtotstarbeliste toetuste, eraldiste menetlemine
Sari
3-4 Riigieelarveliste toetuste lepingud, täitmise aruanded
Toimik
3-4
Vastutaja
Mari Teesalu (Sotsiaalministeerium, Kantsleri vastutusvaldkond, e-teenuste asekantsleri vastutusvaldkond, Analüüsi ja statistika osakond)

Failid

  • 📎3-41165-1 04.08.2020 Riigieelarve eraldise....bdoc1643 KB

Sisu (failidest)

TARID – Thymic Abnormalities in Rare Immunological Diseases CONSORTIUM AGREEMENT for a project under the European Joint Programme on Rare Diseases (EJP RD) Coordinator: University of Helsinki 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 CONTENTS 1 Definitions ................................................................................................................................................................... 4 2 Purpose ....................................................................................................................................................................... 5 3 Duration ...................................................................................................................................................................... 6 3.1 Entry into force ................................................................................................................................................. 6 3.2 Duration and termination ................................................................................................................................. 6 3.3 Survival of rights and obligations ...................................................................................................................... 6 4 Responsibilities of Parties ........................................................................................................................................... 6 4.1 General principles ............................................................................................................................................. 6 4.2 Breach ............................................................................................................................................................... 8 4.3 Involvement of third parties ............................................................................................................................. 8 5 Liability towards each other ....................................................................................................................................... 9 5.1 No warranties .................................................................................................................................................... 9 5.2 Limitations of contractual liability ..................................................................................................................... 9 5.3 Damage caused to third parties ........................................................................................................................ 9 5.4 Force Majeure ................................................................................................................................................... 9 6 Governance structure ................................................................................................................................................. 9 6.1 General structure .............................................................................................................................................. 9 6.2 General Assembly .............................................................................................................................................. 9 6.3 Coordinator ..................................................................................................................................................... 12 7 Financial provisions................................................................................................................................................... 12 7.1 Funding Principles ........................................................................................................................................... 12 7.2 Justifying Costs ................................................................................................................................................ 12 7.3 Financial Consequences of the termination of the participation of a Party ................................................... 12 8 Results....................................................................................................................................................................... 13 8.1 Ownership of Results ...................................................................................................................................... 13 8.2 Joint Ownership .............................................................................................................................................. 13 8.3 Protection of Results ....................................................................................................................................... 14 8.4 Transfer of Results .......................................................................................................................................... 14 8.5 Dissemination .................................................................................................................................................. 14 9 Access Rights............................................................................................................................................................. 15 9.1 Background included ....................................................................................................................................... 15 9.2 General Principles ........................................................................................................................................... 15 9.3 Access Rights for implementation ................................................................................................................... 16 9.4 Access Rights for Exploitation ......................................................................................................................... 16 9.5 Access Rights for Affiliated Entities ................................................................................................................. 16 9.6 Additional Access Rights.................................................................................................................................. 17 9.7 Access Rights for Parties entering or leaving the consortium ......................................................................... 17 9.8 Specific Provisions for Access Rights to Software ........................................................................................... 17 10 Non-disclosure of information............................................................................................................................. 17 10.1 Confidential Information ................................................................................................................................. 17 10.2 Obligations of the Recipient ............................................................................................................................ 17 10.3 Exceptions to Confidentiality obligations ........................................................................................................ 18 10.4 Duty to Notify .................................................................................................................................................. 18 10.5 Personal Data ............................................................................................................ Erreur ! Signet non défini. 1 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 11 Miscellaneous ...................................................................................................................................................... 18 11.1 Attachments, inconsistencies and severability ............................................................................................... 18 11.2 No representation, partnership or agency ...................................................................................................... 19 11.3 Notices and other communication .................................................................................................................. 19 11.4 Assignment and amendments ......................................................................................................................... 19 2 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 THIS CONSORTIUM AGREEMENT is made between 1. The University of Helsinki (“Coordinator” or “UH”) Department: Translational Immunology Research Program Address: Haartmaninkatu 3, P.O. Box 21, FI-00014 University of Helsinki Represented by Research Program Unit Director Henna Tyynismaa 2. Hospital District of Helsinki and Uusimaa (“HUS”) Department: HUS Diagnostic Center, Helsinki University Hospital Address: P.O. box 720, 00029 HUS, Finland Represented by Research Director Anne Pitkäranta 3. Université de Nantes, a scientific, cultural and professional establishment registered under the laws of France established at 1 Quai de Tourville, po box: 13522, 44035 , Nantes CEDEX 1, France Acting in its own name and on behalf of INSERM, in the frame of their joint research unit: « Centre de Recherche en Transplantation et Immunologie” (“UN” U1064) Represented by its president, Olivier LABOUX 4. University of Tartu (“UT”) Department: Institute of Biomedicine and Translational Medicine Address: Ülikooli 18, 50090, Tartu, Estonia Represented by Head of Grant Office Taivo Raud 5. Instituto de Medicina Molecular João Lobo Antunes (“iMM”) Department: N/A Address: Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal Represented by Executive Director Maria M. Mota hereinafter each individually a “Party” and jointly the “Parties” relating to the Project entitled “Thymic Abnormalities in Rare Immunological Diseases”, in short “TARID” hereinafter referred to as the “Project”, and is made on the date of the last signature or on March 1st, 2020 whichever is earlier, hereinafter referred to as the Effective Date. WHEREAS: A. The Parties submitted a proposal to the European Joint Programme on Rare Diseases (“EJP RD”) for the Project, which has been scientifically approved by a review committee. B. The Parties wish to collaborate to carry out the Project as envisaged in the proposal submitted in response to the EJP RD Joint Transnational Call 2019. C. The Parties are funded by the relevant national or regional funding organization(s) of their country and shall enter into an agreement with their respective national funding organizations. D. Some Parties wish to specify or supplement binding commitments among themselves in addition to – but not in conflict with - the provisions of their respective grant award Letters. NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: 3 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 1 DEFINITIONS Words beginning with a capital letter shall have the meaning defined herein. “Access Rights” means rights to use Results or Background under the terms and conditions laid down in this Consortium Agreement. “Background” shall be limited to any data, know-how, material or information, whatever its form or nature, including any intellectual property rights that is held by the Parties before their accession to the Consortium Agreement, and which is Needed for performing the Project or for Exploitation of the Results. The Parties’ Background at the Effective Date of the Consortium Agreement is specified in Attachment 2 hereto. “Consortium Agreement” means this agreement. “Consortium Plan” means the description of the Project in the application submitted to the EJP RD Joint Transnational Call 2019 and the financial plan contained therein, which may be updated by the General Assembly. “Coordinator” means UH. UH has appointed Eliisa Kekäläinen to represent it in its duties as a Coordinator, in case of absence or impediment preventing the appointed person from performing her duties, UH will appoint another person. “Personal Data” means any information relating to an identified or identifiable natural person (‘data subject’); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person. “Defaulting Party” means a Party that the General Assembly has identified to be in breach of this Consortium Agreement. “Dissemination” means disclosing Results to the public by appropriate means (other than those resulting from protecting or exploiting the Results), including in scientific publications (in any medium). “Exploitation” means the direct or indirect utilization of Results, in particular through transfer or licensing by - using them in further contractual research activities with industrial third parties, or - by developing, creating and marketing a product or process, or - for creating and providing a service, or - using them in standardization activities. “Fair and reasonable conditions” means appropriate conditions, including possible financial terms or royalty- free conditions, taking into account the specific circumstances of the request for access, for example the actual or potential value of the Results or Background to which access is requested and/or the scope, duration or other characteristics of the exploitation envisaged “Force Majeure” means any situation or event that: - prevents a Party from fulfilling its obligations under the Consortium Agreement, - was unforeseeable, exceptional situation and beyond the Party’s control, - was not due to error or at least negligence on part of the Party (or on the part of third parties involved in the Project), and - proves to be inevitable in spite of exercising all due diligence - and cannot be overcome despite reasonable endeavors. The following cannot be invoked as Force Majeure: - any default of a service, defect in equipment or material or delays in making them available, unless they stem directly from a relevant case of Force Majeure, - labour disputes or strikes, or - financial difficulties. 4 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 Any situation constituting Force Majeure must be formally notified to the other Parties without delay, stating the nature, likely duration and foreseeable effects. The Parties must immediately take all the necessary steps to limit any damage due to Force Majeure and do their best to resume implementation of the Project as soon as possible. The Party prevented by Force Majeure from fulfilling its obligations under the Consortium Agreement cannot be considered in breach of them. “Intellectual Property” shall mean any and all forms of intellectual property protection, including without limitation, patents, utility models, trademarks, copyright, design rights and unregistered design rights, confidential know how as well as applications for intellectual property protection. “Material” Material means any non-human material and data related thereto which is either owned/stored by a Party before the commencement of the Project or during the Project but outside the Project or collected/generated by a Party in the context and during the execution of the Project which may be transferred between the Parties for the performance of the Project in the frame of a Material Transfer Agreement. Each transfer needs to be accompanied by a transmission sheet, an example is set forth in Attachment 5. "National Funding Organization (NFO)" means the relevant national or regional funding bodies which provide funding to the Parties for their participation in the Project. “Needed” means: (a) for the implementation of the Project: Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Party would be impossible, significantly delayed, or require significant additional financial or human resources. (b) for Exploitation of own Results: Access Rights are Needed if, without the grant of such Access Rights, the Exploitation of own Results would be technically or legally impossible. “Results” means any tangible or intangible output of the Project such as data, knowledge or information, whatever its form or nature, whether it can be protected or not, that is generated in the Project, as well as any rights attached to it, including intellectual property rights. “Software” means sequences of instructions to carry out a process in, or convertible into, a form executable by a computer and fixed in any tangible medium of expression. 2 PURPOSE The purpose of this Consortium Agreement is to establish a consortium between the Parties to conduct the Project, and to specify with respect to the Project the relationship among the Parties, in particular concerning the organization of the work between the Parties, the management of the Project and the rights and obligations of the Parties concerning inter alia liability, Access Rights and dispute resolution. Scientific contact persons for the Project: UH, Eliisa Kekäläinen ([email protected]) and T. Petteri Arstila ([email protected]) HUS, Eliisa Kekäläinen ([email protected]) UN, Carole Guillonneau ([email protected]) and Matthieu Giraud ([email protected]) UT, Pärt Peterson ([email protected]) iMM, Luís Graça ([email protected]) Each Party ensures that this Consortium Agreement is in line with the regulations and conditions of its respective individual grant award letter including the terms and conditions of the individual grant award letter of its respective NFO. In case of conflict, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision. 5 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 3 DURATION 3.1 Entry into force An entity becomes a Party to this Consortium Agreement upon signature of this Consortium Agreement by a duly authorised representative. This Consortium Agreement shall have effect from the Effective Date identified at the beginning of this Consortium Agreement. 3.2 Duration and termination The term of this Agreement is from 01th March 2020 until 30th June 2023 (i.e. corresponding to the term for grants of the EJP RD Joint Transnational Call 2019). However, this Consortium Agreement or the participation of one or more Parties to it may be terminated earlier in accordance with the terms of this Consortium Agreement. If the NFO terminates the grant or a Party’s participation, this Consortium Agreement shall automatically terminate in respect of the affected Party/ies, subject to the provisions surviving the expiration or termination under Article 3.3 of this Consortium Agreement. 3.3 Survival of rights and obligations 3.3.1 The provisions relating to Access Rights, Dissemination and confidentiality, for the time period mentioned therein, as well as for liability, applicable law and settlement of disputes shall survive the expiration or termination of this Consortium Agreement. 3.3.2 Termination shall not affect any rights or obligations of a Party leaving the consortium incurred prior to the date of termination, unless otherwise agreed between the General Assembly and the leaving Party. This includes the obligation to provide all input, deliverables and documents for the period of its participation. 4 RESPONSIBILITIES OF PARTIES 4.1 General principles 4.1.1 Each Party undertakes to take part in the efficient implementation of the Project, and to cooperate, perform and fulfil, promptly and on time, all of its obligations this Consortium Agreement as may be reasonably required from it and in a manner of good faith. 4.1.2 Each Party undertakes to notify promptly, in accordance with the governance structure of the Project, any significant information, fact, problem or delay likely to affect the Project. 4.1.3 Each Party shall promptly provide all information reasonably required by the General Assembly or by the Coordinator to carry out its tasks. 4.1.4 Each Party shall take reasonable measures to ensure the accuracy of any information or materials it supplies to the other Parties. When a Party (the “Provider”) sends biological material to another Party (the “Recipient”) in respect of the Project, a bilateral material and data transfer agreement (MDTA), shall be concluded between such Parties to specify the conditions applying to such transfer of Material or data. The Material or data shall only be used for the purpose of the Project and only for as long as is necessary for that purpose. The Recipient will be entirely responsible for the use of the biological material and/or data and the Provider shall have no obligation or liability for the material, except for gross negligence or willful misconduct. Material and/or data provided in the performance of the Project shall remain the property of the Provider. The Recipient shall not be entitled to transfer the Material or data to any third party (including another Party) without the Provider’s prior written consent. Each Party is responsible for ensuring that the MDTA is adapted to the relevant situation and that it complies with this Consortium Agreement and all applicable rules, laws or regulations in the Parties´ place and country. 6 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 . In the event that one Party (the “Supplier”) transfers Materials and/or Data to another Party (the “Recipient”), the Recipient Party undertakes that all or part of such Material and/or Data: (a) Will only be used for the sole purposes of conducting the Project and only for as long as it is necessary for this purpose, to the exclusion of any other application, in particular for commercial purposes. No express or implied licenses or other rights are provided to the Recipient under any patents, patent applications, trade secrets or other proprietary rights of the Supplier, other than the right to use the Material and/or Data for conducting the Project; (b) Will not be disclosed, distributed, transferred or licensed to a third party, for any purpose whatsoever, without prior written authorization from the Supplier and in accordance with the authorization/declaration necessary for the transfer; (c) Will not be used on human subjects, particularly for clinical trials or diagnostic purposes, except as defined in the Consortium Plan and necessary for the implementation of the Project; (d) Will be used and stored in accordance with the applicable legal and regulatory provisions, notably the provisions relating to the protection of the personal data and to medical secrecy. In particular, the Recipient ensures that it has obtained any necessary authorizations and/or opinions and taken appropriate measures for the storage and use of the concerned Material and/or Data; (e) Will be returned to the Supplier in the event of the withdrawal of the consent or the exercise of the opposition right of the donor which would be communicated by the Supplier to the Recipient; (f) Will no longer be used and will be returned to the Supplier (or destroy, at the Supplier’s discretion) upon request and/or in the event of the termination of this Consortium Agreement and/or upon the expiry thereof and without any copy being made thereof; and (g) Will be used and stored exclusively on the premises of the Recipient within the performance of the Project and by scientists working on the premises of the Recipient or under its direct responsibility and with the same degree of security that it applies to its own Data. Except as specifically agreed otherwise among the relevant Parties in respect of a particular transfer of Material and/or Data upon a separate Material/Data Transfer Agreement, the Recipient acknowledges that the Material and/or Data is a research tool supplied “as is", without any guarantee of any kind, whether express or implied, particularly as regards the preservation, use or manipulation of the Material and/or Data, the fitness and sufficiency or the possibility of using them for a given purpose, or infringement of third party’s rights. In particular, the Data are supplied without any guarantee of any kind, whether express or implied, particularly as regards the possibility of using it for a given purpose. However, Supplier shall use reasonable endeavors to ensure the accuracy of any information it provides. Any Party which is aware of, or becomes aware of, a safety risk, which originates from the Material, shall inform the other Party without delay and provide it with all information in its possession concerning such risks. The Supplier recognizes that it is authorized to transfer the Material and/or Data to the Recipient, and in particular for the purpose of the Project and that the Material and/or the Data were collected in compliance with the applicable laws and regulatory provisions, and notably with the 2018 reform of EU data protection rules, GDPR. The Supplier will communicate to the Recipient all the information at its disposal relating to the preservation and use of the Materials. In any case, the data and/or Material collected by a Party under the Project shall not be transferred to another Party or to a subcontractor or to any third party before any identifying information has been removed by coding or by rendering it anonymous in accordance with all applicable laws and regulations. Any transfer and/or access to Material and/or data shall be evidenced by the execution of a transmission sheet, a template of which is included in Attachment 5, and which may be completed by concerned Parties (notably with regard to the reimbursement and shipping costs) in accordance with this Consortium Agreement. 7 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 As regards human biological materials and/or Personnal Data, Appendix 6 is the MTA template that shall be used for material and/or data owned by HUS, it may be used also by other Parties subject to amendment as needed by the concerned Parties. Each Party using such templates is responsible for ensuring that it is completed correctly, adapted to the relevant situation and that it complies with all applicable rules, laws or regulations, and with the Consortium Agreement, especially concerning the human biological samples importation and exportation and data protection. 4.1.5 Each Party shall ensure that its work on the Project complies fully with all applicable local, government and international laws, regulations and guidelines as applicable in the Party´s place and country which are effective during the period of the Project, including those governing health and safety, data protection, and where relevant, the use of human or animal subjects and good clinical practice. In this regard, each Party shall maintain the confidentiality, in accordance with the applicable laws, regulations and guidelines in the Party´s place and country, of all samples and data relating to the use of human subjects, which is created or used in the course of the Project. 4.1.6 Each Party shall secure all necessary approvals from the relevant research ethics committees before undertaking any part of the Project requiring ethics committee approval and shall, if required, obtain properly signed informed consent and acknowledgement forms from any human subjects, or their legal guardians, who they will involve in the Project. Where any part of the Project takes place in a hospital, the Party involved shall first obtain all necessary approvals, indemnities and agreements from that hospital. 4.2 Data Protection Each Party shall confirm that they comply with the EJP RD ethical requirements (Attachment 7). For the avoidance of doubt, Personal data shall always be treated as confidential, and shall be protected with an adequate level of safety and confidentiality, subject to any applicable legal, regulatory or contractual requirements. When collecting (Data Controller) and processing personal data (Data Processor), the Parties agree to take appropriate measures in order to preserve the confidentiality of personal Data. 4.3 Breach In the event that a responsible Consortium Body identifies a breach by a Party of its obligations under this Consortium Agreement (e.g. improper implementation of the Project), the Coordinator or, if the Coordinator is in breach of its obligations, the Party appointed by the General Assembly, will give formal notice to such Party requiring that the breach will be remedied within 30 calendar days from the date of receipt of the written notice by the Party. If the breach is substantial and is not remedied within that period or is not capable of remedy, the General Assembly may decide to declare the Party to be a Defaulting Party and to decide on the consequences thereof which may include termination of its participation in the Project. 4.4 Involvement of third parties A Party that enters into a subcontract or otherwise involves third parties in the Project remains responsible for carrying out its relevant part of the Project and for such third party’s compliance with the provisions of this Consortium Agreement and of the respective NFO funding decision. It has to ensure that the involvement of third parties does not affect the rights and obligations of the other Parties under this Consortium Agreement and the Grant Agreement. 8 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 5 LIABILITY TOWARDS EACH OTHER 5.1 No warranties In respect of any information or materials (incl. Results and Background) supplied by one Party to another under the Project, no warranty or representation of any kind is made, given or implied as to the sufficiency or fitness for purpose nor as to the absence of any infringement of any proprietary rights of third parties. Therefore, - the recipient Party shall in all cases be entirely and solely liable for the use to which it puts such information and materials, and - no Party granting Access Rights shall be liable in case of infringement of proprietary rights of a third party resulting from any other Party (or its Affiliated Entities) exercising its Access Rights. 5.2 Limitations of contractual liability No Party shall be responsible to any other Party for any indirect or consequential loss or similar damage such as, but not limited to, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a willful act or by a breach of confidentiality. For any remaining contractual liability, a Party’s aggregate liability towards the other Parties collectively shall be limited to once the Party’s share of the total costs of the Project as identified in the Consortium Plan, provided such damage was not caused by a willful act or gross negligence. 5.3 Damage caused to third parties Each Party shall be solely liable for any loss, damage or injury to third parties resulting from the performance of the said Party’s obligations by it or on its behalf under this Consortium Agreement or from its use of Results or Background. 5.4 Force Majeure No Party shall be considered to be in breach of this Consortium Agreement if it is prevented from fulfilling its obligations under the Consortium Agreement by Force Majeure. Each Party will notify the competent Consortium Bodies of any Force Majeure without undue delay. If the consequences of Force Majeure for the Project are not overcome within 6 weeks after such notification, the transfer of tasks - if any - shall be decided by the competent Consortium Bodies. 6 GOVERNANCE STRUCTURE 6.1 General structure The organizational structure of the consortium shall comprise the following Consortium Bodies: General Assembly as the ultimate decision-making body of the consortium The Coordinator is the legal entity acting as the intermediary between the Parties and the EJP RD. The Coordinator shall, in addition to its responsibilities as a Party, perform the tasks assigned to it as described in this Consortium Agreement. 6.2 General Assembly 6.2.1 Members The General Assembly shall consist of one representative of each Party, except for University of Helsinki and CRTI/UN that both have two representatives (hereinafter “Member”). 9 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 Each Assembly Member shall be deemed to be duly authorized to deliberate, negotiate and decide on all matters listed in Section 6.2.7 of this Consortium Agreement, subject to confirmation as need be by the legal representative of each Party. The Coordinator shall chair all meetings of the General Assembly, unless decided otherwise in a meeting of the General Assembly. The Parties agree to abide by all decisions of the General Assembly. This does not prevent the Parties to submit a dispute to resolution in accordance with the provisions of Settlement of disputes in Section 11.8. 6.2.2 Representation in meetings Any Member: - should be present or represented at any meeting; - may appoint a substitute or a proxy to attend and vote at any meeting; - shall participate in a cooperative manner in the meetings. 6.2.3 Preparation and organization of meetings Convening meetings: The chairperson shall convene ordinary meetings of the General Assembly at least once a year, and shall also convene extraordinary meetings at any time upon written request of any Member. Notice of a meeting: The chairperson shall give notice in writing of a meeting to each Member as soon as possible and no later than 20 calendar days preceding an ordinary meeting and 14 calendar days preceding an extraordinary meeting. Sending the agenda: The chairperson shall send each Member a written original agenda no later than 14 calendar days preceding an ordinary meeting, or 10 calendar days before an extraordinary meeting. Adding agenda items: Any agenda item requiring a decision by the Members must be identified as such on the agenda. Any Member may add an item to the original agenda by written notification to all of the other Members no later than 7 calendar days preceding the meeting. During a meeting of the General Assembly the Members present or represented can unanimously agree to add a new item to the original agenda. Other procedural matters: Decisions will only be binding once the relevant part of the minutes has been accepted according to Section 6.3.6 of this Consortium Agreement. Any decision may also be taken without a meeting if the chairperson circulates to all Members a written document which is then signed by the defined majority of Members (see Section 6.2.4). Such document shall include the deadline for responses that cannot be inferior to 15 calendar days. Decisions taken without a meeting shall be considered as accepted if, within the period set out in article 6.2.5, no Member has sent an objection in writing to the chairperson. The decisions will be binding after the chairperson sends to all Members a written notification of this acceptance. Meetings of the General Assembly may also be held by teleconference or other telecommunication means, such as Skype, Teams, etc. 6.2.4 Voting rules and quorum The General Assembly shall not deliberate and decide validly unless two-thirds (2/3) of its Members, including the Coordinator, are present or represented (quorum). 10 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 If the quorum is not reached, the chairperson shall convene another ordinary meeting within 15 calendar days. If in this meeting the quorum is not reached once more, the chairperson shall convene an extraordinary meeting which shall be entitled to decide even if less than the quorum of Members are present or represented. Each Member shall have one vote. Defaulting Parties may not vote. Decisions shall be taken by a majority of two-thirds (2/3) of the votes cast. 6.2.5 Veto rights A Member which can show that its own work, time for performance, costs, liabilities, intellectual property rights or other legitimate interests would be severely affected by a decision of the General Assembly may exercise a veto with respect to the corresponding decision or relevant part of the decision. When the decision is foreseen on the original agenda, a Member may veto such a decision during the meeting only. When a decision has been taken on a new item added to the agenda before or during the meeting, a Member may veto such decision during the meeting and within 15 days after the draft minutes of the meeting are sent. When a decision has been taken without a meeting a Member may veto such decision within 15 calendar days after written notification by the chairperson of the outcome of the vote. In case of exercise of veto, the Members shall make every effort to resolve the matter which occasioned the veto to the general satisfaction of all Members. A Party may not veto decisions relating to its identification as a Defaulting Party. The Defaulting Party may not veto decisions relating to its participation and termination in the consortium or the consequences thereof. A Party requesting to leave the consortium may not veto decisions relating thereto. 6.2.6 Minutes of meetings The chairperson shall produce written minutes of each meeting which shall be the formal record of all decisions taken. The chairperson shall send draft minutes to all Members within 10 calendar days of the meeting. The minutes shall be considered as accepted if, within 15 calendar days from sending, no Member has sent an objection in writing to the chairperson with respect to the accuracy of the draft of the minutes. The chairperson shall send the accepted minutes to all the Members. The Coordinator shall safeguard them. If requested, the Coordinator shall provide authenticated duplicates to Parties. 6.2.7 Decisions The General Assembly shall be free to act on its own initiative to formulate proposals and take decisions in accordance with the procedures set out herein. The following decisions shall be taken by the General Assembly: Content, finances and intellectual property rights - Changes to the Consortium Plan - Modifications to Attachment 1 (Background Included) - Additions to Attachment 3 (List of Third Parties for simplified transfer according to Section 8.4) - Additions to Attachment 4 (Identified Affiliated Entities) Evolution of the consortium - Entry of a new Party to the consortium and approval of the settlement on the conditions of the accession of such a new Party - Withdrawal of a Party from the consortium and the approval of the settlement on the conditions of the withdrawal - Identification of a breach by a Party of its obligations under this Consortium Agreement 11 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 - Declaration of a Party to be a Defaulting Party - Remedies to be performed by a Defaulting Party - Termination of a Defaulting Party’s participation in the consortium and measures relating thereto - Proposal to the EJP RD for a change of the Coordinator - Proposal to the EJP RD for suspension of all or part of the Project - Proposal to the EJP RD for termination of the Project and the Consortium Agreement In the case of abolished tasks as a result of a decision of the General Assembly, Members shall endeavor to rearrange the tasks of the Parties concerned. Such rearrangement shall take into consideration the legitimate commitments taken prior to the decisions, which cannot be cancelled. 6.3 Coordinator 6.3.1 In addition to the general tasks assigned to the Coordinator at Section 6.1, the Coordinator shall be responsible for: - monitoring compliance by the Parties with their obligations - keeping the address list of Members and other contact persons updated and available - collecting, reviewing, and submitting information on the progress of the Project and reports and other deliverables to the EJP RD - preparing the meetings, proposing decisions and preparing the agenda of the General Assembly meetings, chairing the meetings, preparing the minutes of the meetings and monitoring the implementation of decisions taken at meetings - transmitting promptly documents and information connected with the Project - providing, upon request, the Parties with official copies or originals of documents which are in the sole possession of the Coordinator when such copies or originals are necessary for the Parties to present claims. 6.3.2 If one or more of the Parties is late in submission of any project deliverable, the Coordinator may nevertheless submit the other parties’ project deliverables and all other documents required to the EJP RD in time. 6.3.3 If the Coordinator fails in its coordination tasks, the General Assembly may propose to the EJP RD to change the Coordinator. 6.3.4 The Coordinator shall not be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium 6.3.5 The Coordinator shall not enlarge its role beyond the tasks specified in this Consortium Agreement. 7 FINANCIAL PROVISIONS 7.1 Funding Principles The Parties receive funding according to the agreement with their NFO. Each party shall individually bear any additional costs not covered by the received funding necessary to perform their tasks in accordance with the Consortium Plan. 7.2 Justifying Costs In accordance with its own usual accounting and management principles and practices, each Party shall be solely responsible for justifying its costs with respect to the Project towards the respective NFO. Neither the Coordinator nor any of the other Parties shall be in any way liable or responsible for such justification of costs towards the respective NFO. 7.3 Financial Consequences of the termination of the participation of a Party A Defaulting Party shall, within the limits specified in Section 5.2 of this Consortium Agreement, bear any reasonable and justifiable additional costs occurring to the other Parties in order to perform its and their tasks. 12 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 8 RESULTS 8.1 Ownership of Results Results are owned by the Party that generates them. If the researchers of a Party are entitled to claim rights to the Results pursuant to national laws or the funding terms of the NFO in question, the Party concerned must ensure that these researchers comply with the obligations under this Consortium Agreement. If a third party generates Results, the Party concerned must obtain all necessary rights (transfer, licences or other) from the third party, in order to be able to respect its obligations as if those Results were generated by the Party itself. If obtaining the rights is impossible, the Party must refrain from using the third party to generate the Results. 8.2 Joint Ownership Two or more beneficiaries own Results jointly if: (a) they have jointly generated them and (b) it is not possible to separate them for the purpose of applying for, obtaining or maintaining their protection. Where the Joint Results would be generated in part by the staff of a joint research unit (such as an "UMR" Unité Mixte de Recherche.), the establishments managing said unit shall be considered as a single co-owner. It is understood that these establishments shall be personally responsible for the allocation of the co-ownership share allocated to them, pursuant to the agreements in place between them. The joint owners must agree (in writing) on the allocation and terms of exercise of their joint ownership (“Joint Ownership Agreement”), to ensure compliance with their obligations under this Consortium Agreement. Such agreement shall be drawn up as soon as necessary and in any event before any industrial and/or commercial exploitation of the jointly owned Results. This Joint Ownership Agreement shall cover in particular: - How the ownership is divided between the joint owners, - How the jointly owned Results will be protected, including issues concerning the division of the related cost of protection (e.g. patent filing and examination fees, renewal fees, prior state-of (the-art searches, infringement actions, etc.), - How the jointly owned Results will be exploited and disseminated and how the revenues or profits are shared between the joint owners, - The criteria for „fair and reasonable compensation“ to be provided to the non-exploiting joint owners, - How disputes will be settled (e.g. via a mediator, applicable law, etc.). The joint owners agree to endeavor the appointment among them of one joint owner in charge of the management of the jointly owned Results. Unless otherwise agreed in the Joint Ownership Agreement, - each of the joint owners shall be entitled to use their jointly owned Results for non-commercial research activities (which, for the avoidance of doubt, do not include research sponsored by a commercial entity but include own internal non-commercial research and collaborative research with or without public funding) on a royalty-free basis, and without requiring the prior consent of the other joint owner(s), and - each of the joint owners shall be entitled to otherwise Exploit the jointly owned Results and to grant non-exclusive licenses to third parties (without any right to sub-license), if the other joint owners are given: (a) at least 45 calendar days advance notice; and (b) fair and reasonable compensation. The joint owners shall agree on all protection measures and the division of related cost in advance. 13 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 Once the Results have been generated, joint owners may agree (in writing) to apply another regime than joint ownership (such as, for instance, transfer to a single owner) but they must ensure that access rights granted under this agreement are respected. 8.3 Protection of Results The possible obligation of a Party to protect any Results is determined by the funding terms of the NFO in question. 8.4 Transfer of Results Each Party may transfer ownership of its own Results observing the limitations set forth herein. A Party that intends to transfer ownership of Results must give at least 45 days prior notice (or less if unanimously agreed in writing) to the other Parties. The Parties recognize that in the framework of a merger or an acquisition of an important part of its assets, it may be impossible under applicable EU and national laws on mergers and acquisitions for a Party to give the full 45 calendar days prior notice for the transfer. Each party may identify specific third parties it intends to transfer the ownership of its Results to in Attachment 3 to this Consortium Agreement. The other Parties hereby waive their right to prior notice and their right to object to a transfer to listed third parties. The transferring Party shall, however, at the time of the transfer, inform the other Parties of such transfer and shall ensure that the rights of the other Parties will not be affected by such transfer. Any addition to Attachment 3 after signature of this Agreement requires a decision of the General Assembly. The obligations above apply only for as long as other Parties still have - or still may request - Access Rights to the Results. 8.5 Dissemination For the avoidance of doubt, nothing in this Section 8.5 has impact on the confidentiality obligations set out in Section 10. 8.5.1 Dissemination of own Results During the Project and for a period of 1 year after the end of the Project, the Dissemination of own Results by one or several Parties including but not restricted to publications and presentations, shall be subject to the following provisions. Prior notice of any planned publication shall be given to the other Parties at least 45 calendar days before the submission of the publication. Any objection to the planned publication shall be made in accordance with this Consortium Agreement in writing to the Coordinator and to the Party or Parties proposing the dissemination within 30 calendar days after receipt of the notice. If no objection is made within the time limit stated above, the publication is permitted. An objection is justified if - the protection of the objecting Party's Results or Background would be adversely affected and/or - the objecting Party's legitimate academic or commercial interests in relation to the Results or Background would be significantly harmed. The objection has to include a precise request for necessary modifications. If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned publication and/or by protecting information before publication) and the objecting Party shall not unreasonably continue the opposition if appropriate measures are taken following the discussion. 14 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 The objecting Party can request a publication delay of not more than 90 calendar days from the time it raises such an objection. After 90 calendar days the publication is permitted, provided that Confidential Information of the objecting Party has been removed from the Publication. Possible open access obligations are determined by the funding terms of the respective NFO. Authorship on publications shall be based on academic standards and custom. In accordance with normal academic practice, all investigators and contributors to a publication will be acknowledged, always in compliance with recognized standards concerning publication and authorship. 8.5.2 Dissemination of another Party’s unpublished Results or Background A Party shall not include in any dissemination activity another Party's Results or Background without obtaining the owning Party's prior written approval, unless they are already published. 8.5.3 Dissemination by NFO’s Certain NFOs that are providing funding to Parties for their performance of their tasks under the Project, require having the unlimited and unrestrictive right to publish the own Results of the Party that receives funding therefrom. Consequently, notwithstanding anything contained to the contrary in this Agreement, such NFO’s shall be permitted to publish at their own discretion and without any limitations, the own Results of the Party that receives funding therefrom (including without limitation also own Results jointly owned with another Party to the Project). Before any dissemination of jointly owned Results, the NFO has to obtain permission from all joint owners. 8.5.4 Cooperation obligations The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any dissertation or thesis for a degree which includes their Results or Background subject to the confidentiality and publication provisions agreed in this Consortium Agreement. 8.5.5 Use of names, logos or trademarks Nothing in this Consortium Agreement shall be construed as conferring rights to use in advertising, publicity or otherwise the name of the Parties or any of their logos or trademarks without their prior written approval. Display of the EJP-RD logo and the logo of the relevant NFO(s) shall be included in any project-specific promotional material, press releases, reports, presentations and external websites, following the respective logo guidelines of each organization. 9 ACCESS RIGHTS 9.1 Background included In Attachment 1, the Parties have identified and agreed on the Background for the Project and have also, where relevant, informed each other that Access to specific Background is subject to legal restrictions or limits. For the avoidance of doubt, all Background used in connection with the Project shall remain the property of the Party introducing the Background. Anything not identified in Attachment 1 shall not be the object of Access Right obligations regarding Background. Any Party may add further own Background to Attachment 1 during the Project by written notice to the other Parties. However, approval of the General Assembly is needed should a Party wish to modify or withdraw its Background in Attachment 1. 9.2 General Principles Each Party shall implement its tasks in accordance with the Consortium Plan and shall bear sole responsibility for ensuring that its acts within the Project do not knowingly infringe third party property rights. Any Access Rights granted expressly exclude any rights to sublicense unless expressly stated otherwise. 15 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 Access Rights shall be free of any administrative transfer costs. Access Rights are granted on a non-exclusive basis. Results and Background shall be used only for the purposes for which Access Rights to it have been granted. All requests for Access Rights shall be made in writing. The granting of Access Rights may be made conditional on the acceptance of specific conditions aimed at ensuring that these rights will be used only for the intended purpose and that appropriate confidentiality obligations are in place. The requesting Party must show that the Access Rights are Needed. A request for Access Rights may be made up to twelve months after the end of the Project or, in the case of Section 9.7.2, after the termination of the requesting Party’s participation in the Project. Waivers of access rights are not valid unless in writing. 9.3 Access Rights for implementation Access Rights to Results and Background Needed for the performance of the own work of a Party under the Project shall be granted on a royalty-free basis, unless otherwise agreed for Background in Attachment 1. 9.4 Access Rights out of the Project 9.4.1 Access Rights to Results Access Rights to Results if Needed for Exploitation of a Party's own Results shall be granted on Fair and Reasonable conditions. Access rights to Results for internal research activities shall be granted on a royalty-free basis. 9.4.2 Access Rights to Background Access Rights to Background if Needed for Exploitation of a Party's own Results, including for research on behalf of a third party, shall be granted on Fair and Reasonable conditions. 9.5 Access Rights for Affiliated Entities Affiliated Entities have Access Rights under the conditions of this Consortium Agreement. Access Rights must be requested by the Affiliated Entity from the Party that holds the Background or Results. Alternatively, the Party granting the Access Rights may individually agree with the Party requesting the Access Rights to have the Access Rights include the right to sublicense to the latter's Affiliated Entities if they are listed in Attachment 4. Access Rights to Affiliated Entities shall be granted on Fair and Reasonable conditions and upon written bilateral agreement. Affiliated Entities which obtain Access Rights in return fulfil all confidentiality and other obligations accepted by the Parties under this Consortium Agreement as if such Affiliated Entities were Parties. Access Rights may be refused to Affiliated Entities if such granting is contrary to the legitimate interests of the Party which owns the Background or the Results. Access Rights granted to any Affiliated Entity are subject to the continuation of the Access Rights of the Party to which it is affiliated, and shall automatically terminate upon termination of the Access Rights granted to such Party. Upon cessation of the status as an Affiliated Entity, any Access Rights granted to such former Affiliated Entity shall lapse. Further arrangements with Affiliated Entities may be negotiated in separate agreements. 16 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 9.6 Additional Access Rights For the avoidance of doubt, any grant of Access Rights not covered by this Consortium Agreement shall be at the absolute discretion of the owning Party and subject to such terms and conditions as may be agreed between the owning and receiving Parties. 9.7 Access Rights for Parties entering or leaving the consortium 9.7.1 New Parties entering the consortium As regards Results developed before the accession of the new Party, the new Party will be granted Access Rights on the conditions applying for Access Rights to Background. 9.7.2 Parties leaving the consortium 9.7.2.1 Access Rights granted to a Defaulting Party Access Rights granted to a Defaulting Party and such Party's right to request Access Rights shall cease immediately upon receipt by the Defaulting Party of the formal notice of the decision of the General Assembly to terminate its participation in the consortium. 9.7.2.2 Access Rights granted to a non-defaulting Party: A non-defaulting Party leaving voluntarily and with the other Parties' consent shall have Access Rights to the Results developed until the date of the termination of its participation. It may request Access Rights within the period of time specified in Section 9.2. 9.7.2.3 Access Rights to be granted by any leaving Party Any Party leaving the Project shall continue to grant Access Rights pursuant to this Consortium Agreement as if it had remained a Party for the whole duration of the Project. 9.8 Specific Provisions for Access Rights to Software For the avoidance of doubt, the general provisions for Access Rights provided for in this Section 9 are applicable also to Software. Parties’ Access Rights to Software do not include any right to receive source code or object code ported to a certain hardware platform or any right to receive respective Software documentation in any particular form or detail, but only as available from the Party granting the Access Rights. 10 NON-DISCLOSURE OF INFORMATION 10.1 Confidential Information All information in whatever form or mode of communication, which is disclosed by a Party (the “Disclosing Party”) to any other Party (the “Recipient”) in connection with the Project during its implementation and which has been explicitly marked as “confidential” at the time of disclosure, or when disclosed orally has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 calendar days from oral disclosure at the latest as confidential information by the Disclosing Party, is “Confidential Information”. 10.2 Obligations of the Recipient The Recipients hereby undertake, for a period of 4 years after the end of the Project - not to use Confidential Information otherwise than for the purpose for which it was disclosed; - not to disclose Confidential Information without the prior written consent by the Disclosing Party; - to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and - to return to the Disclosing Party, or destroy, on request all Confidential Information that has been disclosed to the Recipients including all copies thereof and to delete all information stored in a 17 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 machine readable form to the extent practically possible. The Recipients may keep a copy to the extent it is required to keep, archive or store such Confidential Information because of compliance with applicable laws and regulations or for the proof of on-going obligations provided that the Recipient comply with the confidentiality obligations herein contained with respect to such copy for as long as the copy is retained. The recipients shall be responsible for the fulfilment of the above obligations on the part of their employees or third parties involved in the Project and shall ensure that they remain so obliged, as far as legally possible, during and after the end of the Project and/or after the termination of the contractual relationship with the employee or third party. The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Project as with its own confidential and/or proprietary information, but in no case less than reasonable care 10.3 Exceptions to Confidentiality obligations The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that: - the Confidential Information has become or becomes publicly available by means other than a breach of the Recipient’s confidentiality obligations; - the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer confidential; - the Confidential Information is communicated to the Recipient without any obligation of confidentiality by a third party who is to the best knowledge of the Recipient in lawful possession thereof and under no obligation of confidentiality to the Disclosing Party; - the disclosure or communication of the Confidential Information is foreseen by provisions of the Grant Agreement; - the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Party; - the Confidential Information was already known to the Recipient prior to disclosure, or - the Recipient is required to disclose the Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, subject to the provision Section 10.7 hereunder. 10.4 Duty to Notify Each Party shall promptly advise the other Party in writing of any unauthorised disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorised disclosure, misappropriation or misuse. If any Party becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure - notify the Disclosing Party, and - comply with the Disclosing Party’s reasonable instructions to protect the confidentiality of the information. 11 MISCELLANEOUS 11.1 Attachments, inconsistencies and severability This Consortium Agreement consists of this core text and - Attachment 1 (Background included) - Attachment 2 (Accession document) - Attachment 3 (List of Third Parties for simplified transfer according to Section 8.4) - Attachment 4 (Identified Affiliated Entities) 18 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 - Attachment 5 (Form for transfer of biological materials - Attachment 6 : HUS MTA agreement with 3 annexes) - Attachment 7 (Commitment to EJP RD ethical requirements) In case of conflicts between the attachments and the core text of this Consortium Agreement, the latter shall prevail. Should any provision of this Consortium Agreement become invalid, illegal or unenforceable, it shall not affect the validity of the remaining provisions of this Consortium Agreement. In such a case, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated that fulfils the purpose of the original provision. 11.2 No representation, partnership or agency No Party shall be entitled to act or to make legally binding declarations on behalf of any other Party or of the consortium. Nothing in this Consortium Agreement shall be deemed to constitute a joint venture, agency, partnership, interest grouping or any other kind of formal business grouping or entity between the Parties. 11.3 Notices and other communication Any notice to be given under this Consortium Agreement shall be in writing to the addresses and recipients as listed in the most current address list kept by the Coordinator. Formal notices: If it is required in this Consortium Agreement (Sections 4.3, 9.7.2.1, and 11.4) that a formal notice, consent or approval shall be given, such notice shall be signed by an authorized representative of a Party and shall either be served personally or sent by mail with recorded delivery. Other communication: Other communication between the Parties may also be effected by other means such as e-mail with acknowledgement of receipt, which fulfils the conditions of written form. Any change of persons or contact details shall be notified immediately by the respective Party to the Coordinator. The address list shall be accessible to all concerned. 11.4 Assignment and amendments Except as set out in Section 8.2, no rights or obligations of the Parties arising from this Consortium Agreement may be assigned or transferred, in whole or in part, to any third party without the other Parties’ prior formal approval. Amendments and modifications to the text of this Consortium Agreement not explicitly listed in Section 6.2.7 require a separate written agreement to be signed between all Parties. 11.5 Mandatory national law Nothing in this Consortium Agreement shall be deemed to require a Party to breach any mandatory statutory law under which the Party is operating. 11.6 Language This Consortium Agreement is drawn up in English, which language shall govern all documents, notices, meetings, arbitral proceedings and processes relative thereto. 11.7 Applicable law This Consortium Agreement shall be construed in accordance with and governed by the laws of Belgium excluding its conflict of law provisions. 19 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 11.8 Settlement of disputes The parties shall endeavour to settle their disputes amicably. If, however, no settlement of any dispute under this Consortium Agreement has been possible to achieve, after the Parties’ reasonable endeavours to settle such dispute(s) amicably, the Parties agree to submit the matter to settlement proceedings under the International Chamber of Commerce Alternative Dispute Resolution (ADR) Rules. If, and to the extent that, any such dispute, controversy or claim has not been settled pursuant to the mediation within 60 calendar days following the filing of a request for ADR pursuant to the said Rules, the courts of Brussels shall have exclusive jurisdiction. Nothing in this Consortium Agreement shall limit the Parties' right to seek injunctive relief in any applicable competent court 12 SIGNATURES AS WITNESS: The Parties have caused this Consortium Agreement to be duly signed by the undersigned authorised representatives. UNIVERSITY OF HELSINKI (“UH”) Henna Tyynismaa Director of Research Programs Unit, University of Helsinki HOSPITAL DISTRICT of HELSINKI AND UUSIMAA (“HUS”) Anne Pitkäranta Research Director Université de Nantes (UN) For the legal representative, per delegation Sébastien YOUINOU Director of research, partnerships and innovation 20 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 University of Tartu (“UT”) Taivo Raud Head of Grant Office INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES Maria M. Mota Executive Director 21 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 1: BACKGROUND INCLUDED According to the Consortium Agreement Background is defined as “data, know-how or information (…) that is needed to implement the action or exploit the results”. Because of this need, Access Rights have to be granted in principle, but Parties must identify and agree amongst them on the Background for the project. This is the purpose of this attachment. This represents the status at the time of signature of this Consortium Agreement. PARTY 1: UNIVERSITY OF HELSINKI As to the University of Helsinki, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of University of Helsinki shall be Needed by another Party for implementation of the Project or Exploitation of that other Party’s Results. This represents the status at the time of signature of this Consortium Agreement. PARTY 2 HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA As to the Hospital District of Helsinki and Uusimaa, it is agreed between the Parties that, to the best of their knowledge, No data, know-how or information of Hospital District of Helsinki and Uusimaa shall be Needed by another Party for implementation of the Project or Exploitation of that other Party’s Results. This represents the status at the time of signature of this Consortium Agreement. PARTY 2: UNIVERSITE DE NANTES As to Université de Nantes, it is agreed between the Parties that, to the best of their knowledge, the following background is hereby identified and agreed upon for the Project. Specific limitations and/or conditions, shall be as mentioned hereunder: Describe Background Specific limitations and/or Specific limitations and/or conditions for implementation conditions for Exploitation Thymics APCs rat model Complementary provisions to the Not available for Access Rights by MTA clauses in the Agreement may the Parties for Exploitation be added if necessary. This represents the status at the time of signature of this Consortium Agreement. PARTY 3: UNIVERSITY OF TARTU As to the University of Tartu, it is agreed between the Parties that, to the best of their knowledge, no data, know-how or information of University of Tartu shall be Needed by another Party for implementation of the Project or Exploitation of that other Party’s Results. This represents the status at the time of signature of this Consortium Agreement. PARTY 4: INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES As to INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES, it is agreed between the Parties that, to the best of their knowledge, the following background is hereby identified and agreed upon for the Project. 22 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 Describe Background Specific limitations and/or conditions Specific limitations and/or conditions for implementation (Article 25.2 for Exploitation (Article 25.3 Grant Grant Agreement) Agreement) Identification of germinal centres none none based on the phenotype of Tfh and Tfr cells within the tissue Transcriptional signatures of Tfh, Tfr none none and regulatory T cells (Treg) cells from tissues with GCs (tonsil) and without GCs (LN and blood). This represents the status at the time of signature of this Consortium Agreement. 23 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 2: ACCESSION DOCUMENT ACCESSION of a new Party to [Acronym of the Project] Consortium Agreement, version […, YYYY-MM-DD] [OFFICIAL NAME OF THE NEW PARTY AS IDENTIFIED IN THE Grant Agreement] hereby consents to become a Party to the Consortium Agreement identified above and accepts all the rights and obligations of a Party starting [date]. [OFFICIAL NAME OF THE COORDINATOR AS IDENTIFIED IN THE Grant Agreement] hereby certifies that the consortium has accepted in the meeting held on [date] the accession of [the name of the new Party] to the consortium starting [date]. This Accession document has been done in 2 originals to be duly signed by the undersigned authorised representatives. [Date and Place] [INSERT NAME OF THE NEW PARTY] Signature(s) Name(s) Title(s) [Date and Place] [INSERT NAME OF THE COORDINATOR] Signature(s) Name(s) Title(s) 24 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 3: LIST OF THIRD PARTIES FOR SIMPLIFIED TRANSFER ACCORDING TO SECTION 8.4. For Nantes Université: SATT OUEST VALORISATION (TTO) ATTACHMENT 4: IDENTIFIED AFFILIATED ENTITIES ACCORDING TO SECTION 9.5 NONE 25 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 5: FORM FOR TRANSFER OF BIOLOGICAL MATERIALS AND / OR DATA The Supplier (as defined below) agrees to the transfer of or access to the Material and/or Data (described below) to the Recipient (as defined below) for the conduct of the Project in accordance with the terms and conditions of the Consortium Agreement TARID No. …………….. Materials Designation: ……………………………………………………………………. Quantities: ……………………………………………………………………. Data Designation: ……………………………………………………………………. Form: ……………………………………………………………………. Party supplying or giving access to the ……………………………………………………………………. Material and/or Data (the “Supplier”) Name and address of the laboratory supplying ……………………………………………………………………. or giving access to the Material and/or Data Contact details of the scientist supplying or Name: …………………………………………………………….. giving access to the Material and/or Data Email: ……………………………………………………………. Tel: ……………………………………………………………….. Fax: ………………………………………………………………. Recipient party for the Material and/or Data ………………………………….…………………………………. (the “Recipient”) Delivery address for the Material and/or Data Address ………………………………………………………….. …………………………………………………………………….. Name of recipient ………………………………………………. Email: …………………………………………………….………. Tel: ……………………………………………………….……….. Fax: ……………………………………………………….………. Signed in [-](-) original counterparts drafted in the English language, with one (1) for the Supplier and the other(s) for the Recipient Witnessed, the Scientific Manager of Supplier Witnessed, the Scientific Manager of Recipient 26 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 5: TEMPLATE FOR MATERIAL TRANSFER AGREEMENT FOR MATERIALS OWNED BY HUS INCLUDING ATTACHMENTS A, B, C MATERIAL TRANSFER AGREEMENT 1. PARTIES This agreement on the transfer of biological materials ("agreement") is signed between the sample principal, responsible for sample: Hospital District of Helsinki and Uusimaa (hereinafter referred to as ”HUS”) Stenbäckinkatu 9, P.O.Box 100, FI-00029 Helsinki, Finland Business ID 1567535-0 and University, Institution or Company (hereinafter referred to as ”recipient”) Registered address Business ID hereafter together referred to as “parties”. Recipient cannot assign or sublicense its rights or obligations under this agreement to any third party without the prior written permission of HUS. WHEREAS Parties are already engaged in collaborative research in the frame of the European Joint Programme on Rare Diseases (“EJP RD”). The present MTA takes place in the contexte the TARID (Thymic Abnormalities in Rare Immunological Diseases) project. Parties are already bound by the TARID Consortium Agreement (2020_00105), together with third Parties. 2. TRANSFER OF BIOLOGICAL MATERIALS AND DATA HUS is in possession of a certain biological materials, samples and associated personal data (“Material”), which need to be analyzed within the framework of the research project of the recipient. HUS collaborates with the principal investigator for the specific research project (see paragraph 4). The parties wish the recipient to be able to analyze the Material(s) in a research project and the HUS agrees to make the mentioned Material available to the recipient for the specific research project purposes. HUS undertakes to assist the recipient with the transfer of the Material(s) specified in attachment 1, for specific analyses/research. Material(s) for analysis/research is provided in pseudonymized form, i.e. coded samples and coded personal data so that an individual donor cannot be identified. HUS undertakes to keep a code key for the identification of samples/Material during the term of this agreement. The recipient acknowledges that HUS cannot send any information about the sample/ Material(s) that can identify the sample donor to recipient. Personal data under this agreement means any information that is directly or indirectly attributable to a natural person. All rights and title to the transferred Material(s) remain with the HUS. Recipient shall cover any reasonable work, shipping and related costs, unless otherwise agreed. The fee for the said costs is [approximately] in the amount of: [Insert the possible fee]. 27 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 3. PERMITTED USE Recipient declares that research project has been approved by an ethics committee/IRB. HUS makes no representations that the use does not infringe any rights of third parties and makes no representation and gives no warranty or undertaking, in relation to the Material(s). As examples, but without limiting the foregoing, HUS gives no warranty: i) that it owns all necessary property and other rights in the Material(s) and that their use will not infringe any patent, copyright, trade mark or other right owned by any third party; or ii) that the Material(s) are of merchantable or satisfactory quality or fit for any particular purpose, have been developed with reasonable care and skill or tested for the presence of pathogens or otherwise, or are viable, safe or non-toxic. The recipient acknowledges that the Material(s) is made available for experimental use only and should not be used in humans. The recipient agrees to use the submitted Material(s), solely as described in attachment 2, in accordance with applicable laws, regulations, policies, guidelines, ethical standards and under all circumstances solely according to the patient’s consent. 4. ACCESS TO THE MATERIALS The recipient agrees to ensure that only those persons involved in the research project and principal investigator have access to and the use of the Material(s) for the research. The recipient shall take all reasonable measures to secure the safety and confidentiality of the Material(s), any derivatives and data and for that purpose, but without limitation, shall ensure that all research personnel are similarly bound by appropriate undertakings contained in the contracts under which such research personnel are employed or render services to the recipient, or otherwise as appropriate in the circumstances. (“PI of the recipient”): [Insert the name, department and address of the scientist receiving the material] 5. SECURITY FOR MATERIALS The recipient ensures that Material(s) is protected from unauthorized use and of theft. The recipient agrees to abide by and meet the requirements and instructions from HUS in attachment 3. The recipient acknowledges that it under no circumstances shall use the Material(s) transferred under this agreement to identify individuals or to contact any individual whose biological material it has dealt with. If the recipient becomes aware of any unauthorized use or disclosure of the use of Material(s), the recipient undertakes to contact HUS without delay. 6. RESULTS AND PUBLICATIONS Parties will apply section 8 of the TARID Consortium Agreement. 7. INDEMNITY HUS is not responsible for the recipient´s use of Material(s) and in case of loss, damage or liability which may arise from or in connection with this agreement or the equivalent in case of storage or transport of Material(s) to the recipient. 28 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 Subject to section 5 of the TARID Consortium Agreement, the recipient agrees to indemnify and hold harmless HUS and its employees, whether in contract, delict or otherwise, against any loss, claim, and damage caused as a result of the use, keeping, storage or transport of the Material(s) or the consequences of its use under this agreement – including but not limited to i) injury to the recipient and/or its employees and third parties; ii) infringement of third party intellectual property rights and iii) use of the Materials within or outside the scope of this agreement. The recipient is liable to HUS for any damage caused to HUS or the patients by third parties it has transferred to or disclosed the Material(s). 8. TERM AND TERMINATION OF THIS AGREEMENT This agreement shall enter into force on [date] and shall remain in force for two (2) years or until research under the research plan has been completed, whichever occurs first. This agreement may be terminated by either party for any reason, by giving the other party thirty (30) day´s written notice. HUS has the right to terminate this agreement with immediate effect if the recipient is in breach of its obligations under this agreement or is bankrupt or under liquidation. All confidentiality and other obligations of a continuing nature contained herein shall remain in force and shall survive this agreement notwithstanding its termination as aforesaid. 9. TERMINATION OF TREATMENT OF MATERIALS AND DATA The recipient agrees on expiry of this agreement to stop the use of the Material(s). Unless otherwise agreed between the Parties, the recipient also agrees to return or destroy the Material(s) and any copies of coded personal data obtained by recipient as instructed by HUS, when the research according to the research plan is complete, or within thirty (30) days after termination or expiration of this agreement, whichever occurs first. The principal investigator and the recipient are responsible for the destruction or return of the Material(s). The recipient shall however have the right to retain such copies as are required to comply with applicable laws, rules and regulations. 10. OTHER No provision of this agreement may be amended or modified, except by written instrument duly executed by the parties. All communications concerning this agreement shall be in writing and shall be delivered to the address indicated below, unless party has specifically been notified by the other party of another address for this purpose. Message is delivered in person, by mail, e-mail or fax. A receipt shall always be provided for each received message. 11. APPLICABLE LAW AND DISPUTES 29 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 This Agreement shall be governed by and construed in accordance with the laws of Finland or with the laws of the jurisdiction of the origin of the sample without regard to its conflict of laws rules. Any dispute, controversy or claim arising out of or in connection with this Agreement shall be resolved amicably. In case an amicable resolution is not agreed upon within 30 days, a Party may take the dispute to be finally settled by the District Court of Helsinki or by the local Court of the jurisdiction of the origin of the sample. This agreement is executed in two (2) originals, where both parties have taken one (1) each. HOSPITAL DISTRICT OF HELSINKI AND UUSIMAA ____/___.2019 _________________________ _____________________ Anne Pitkäranta, [insert name], Research Director toimialan tutkimuksen ja opetuksen vastuuhenkilö RECIPIENT: ____/____.2019 __________________________ ______________________________ 30 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 1 TO HUS MTA: BIOLOGICAL MATERIAL Description of biological material and personal data to be transferred. Pseudonymized and patient unidentifiable to recipient xxx [insert sample type], samples from [patient type with diagnosis] in the amount of [number of samples, type of samples for instance plasma, serum, urine etc. each identified in number] --- previously collected by HUS for [insert study/research/purpose for collecting and to what end they were collected]. Minor changes in the amounts indicated above may occur. ATTACHMENT 2 TO HUS MTA: RESEARCH TO BE CONDUCTED Research Plan: Detailed specification of the purposes for which biological material and personal data may be used: HUS’s materials, will be used for assessment of [insert the following: - the purpose and study or research for which the samples shall be used - what organization and to which department/unit etc]. All samples are identified by a numerical code; patient-identifiable data are not available to recipient. 31 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 ATTACHMENT 3 TO HUS MTA: INFORMATION SECURITY ANNEX 1. Purpose and application of this document This document is an annex to the Agreement concluded between the Parties to the TARID consortium Agreement (hereafter “the Contracting Parties”) by which matters related to the data protection, information security and processing and secrecy of a Contracting Party’s material of the subject of the Agreement are agreed upon. This document shall be applied in accordance with the order of precedence of contract documents stated in the Agreement, with due regard to what is stated below on the application of potential limitations of liability under the Agreement. 2. Definitions Personal data: means any information relating to an identified or identifiable natural person (‘data subject’); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person.Defined in Article 4 of the Data Protection Regulation. Processing of personal data: Defined in Article 4 of the Data Protection Regulation Processing of personal data refers, for example, to the Processor's opportunity to view personal data in connection with the implementation of the subject of the Agreement. Data Protection Regulation or GDPR: Regulation (EU) 2016/679 of the European Parliament and of the Council on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC. Material: documents, written information, databases and software to be used in connection with the supply of the product or in connection with the service, and other material that a Party has submitted to the Processor for the purpose of providing a product or a service, including data material that is created when the service or product is used, its design, structure and metadata. The structure of the data material does not refer to its structure in terms of storage technology but to its conceptual design and parsing for the purposes of use. Storage technically, the data material can be contained in files, databases or other storage formats. In this definition, data content and data refer to both raw data and processed data. 3. General obligations a. Contracting Parties’ obligation to comply with legislation The Contracting Parties undertake to comply with the legislation on information security, data protection, publicity and confidentiality and the official regulations issued thereunder. The Agreement shall not derogate from the mandatory obligations imposed on a Contracting Party by law. b. Obligation to co-operate The Contracting Parties shall use all reasonable endeavours to contribute to the attainment of a high level of information security in the implementation of the subject of the Agreement and to the other Contracting Party’s opportunity to maintain it on its own part. c. Due care obligation The Contracting Parties shall ensure that the duties foreseen hereunder are carried out with due care and that the confidentiality, availability or integrity of CONTROLLER’s material or confidential information is not endangered as a result of negligence, incorrect working methods or other conduct at variance with the Agreement. d. Duties and responsibilities related to information security The Contracting Parties shall define the duties and responsibilities related to information security in their respective organisations, assign persons in charge with sufficient experience and competence, and communicate their contact details to the other Contracting Party. e. In-house instructions related to information security 32 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 The Contracting Parties may have separate in-house instructions related to information security. The Contracting Parties shall comply with them insofar as they are not in conflict with the Agreement. The Contracting Parties shall take the other Party’s in-house instructions related to information security into account as far as possible. 4. CONTROLLER's material a. Handling In the handling of CONTROLLER’s material, the Processor shall comply with the good practice on information management in accordance with the legislation applicable in medical research, the good data processing practice required under data protection legislation, other legislation concerning the protection of data and privacy protection, other applicable legislation mentioned in the Agreement as well as reasonable instructions given by CONTROLLER. If the Processor prepares or processes patient documents under the Agreement, the Processor commits to preparing and processing the said documents in accordance with the specific the rules for preparing and processing patient documents and the instructions given by CONTROLLER as the controller. b. Intended use The Processor may only use CONTROLLER’s material for the implementation of the subject of the Agreement and only to the extent that is necessary for the implementation of the subject of the Agreement. The Processor shall see to it that the CONTROLLER’s material is only processed by authorised research personnel working for and on behalf of the Processor whose work duties involve the processing CONTROLLER’s material. c. Information security levels CONTROLLER shall have the right to define different information security levels and related special information security measures and instructions for CONTROLLER’s material. The Processor shall process CONTROLLER's material in accordance with the requirements for its information security level. In the event that changes to the information security levels give rise a substantial amount of additional work for the Processor, the Contracting Parties shall address the matter in accordance with the change management procedure. d. Information requests The Processor shall forward any third-party information requests concerning CONTROLLER’s material immediately to CONTROLLER. e. Returning CONTROLLER’s material Upon expiry of the Agreement or when the need to use the material no longer exists, the Processor shall return CONTROLLER’s up-to-date material to CONTROLLER within 14 days of CONTROLLER’s written request to this effect in accordance with the data material openness requirement, unless otherwise agreed upon in the Agreement. The data material openness requirement means that the data material of CONTROLLER is available in a generally used format and accessible with generally used information systems without any royalties or licence fees or other conditions limiting its use. The Processor is not entitled to any separate compensation for the delivery of CONTROLLER's material in accordance with this subparagraph 5.5. f. Destroying CONTROLLER’s material The Processor shall, at its own cost, destroy any copies of CONTROLLER's material in a data secure manner when CONTROLLER has confirmed, in writing, that CONTROLLER’s material had been returned in accordance with the Agreement. The Processor shall, at CONTROLLER’s request, present reasonable evidence of destroying the material without any separate compensation. The Processor is not liable to destroy the material if the Processor is obligated to retain the material concerned under law or official regulation. 5. Processing of personal data This paragraph 6 shall apply in the event that the Processor processes personal data under the Agreement. Also the conditions concerning CONTROLLER's material, among others, shall be applied to the processing of personal data. a. Processor’s right to process personal data CONTROLLER is within the meaning of data protection legislation and the Processor, a processor of personal data. 33 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 The Processor shall have the right to process the personal data contained in CONTROLLER’s material only on the grounds indicated in the Agreement or with CONTROLLER’s prior written permission; only to the extent and as long as it is necessary for the implementation of the subject of the Agreement; only in accordance with the data subjects’ consent and/or valid permits, as indicated in the Agreement; only in accordance with this Agreement and the documented instructions separately given by CONTROLLER. The following matters are addressed in greater detail in the Project, other annexes hereto or other documentation related to the Agreement: the subject and duration of the processing of personal data; the nature and purpose of the processing of personal data; the type of the personal data; the categories of data subjects; the controller’s obligations and rights (insofar as they have not been indicated in this Annex). b. Complying with data protection legislation In the processing of personal data, the Processor undertakes to comply with the current data protection legislation and the official regulations issued thereunder. The Processor warrants that it is familiar with the content of the Data Protection Regulation, for example, including, but not limited to, the obligations imposed on a processor in Articles 28 and 32. Any conduct of the Processor that is contrary to the data protection legislation may be considered a material breach of contract. The Processor shall immediately notify CONTROLLER if it suspects that the Agreement or the instructions or any practice used in the implementation of the subject of the Agreement are at variance with data protection legislation. c. Actions to secure compliance with the requirements of data protection legislation The Processor is required to assess the risks associated with processing of personal data in view of the data subjects and to implement appropriate technical and organisational measures to ensure that the processing of personal data meets the requirements of data protection legislation and to safeguard the protection of the rights of the data subject. The technical and organisational measures must be recorded in writing and the documentation must be kept up-to- date. Among other things, the Processor shall see to the proper protection of the personal data it processes to ensure their confidentiality, integrity and availability, and abide by the principle of data protection by design and by default in the implementation of the subject of the Agreement. The Processor shall designate a data protection officer pursuant to Article 37 of the Data Protection Regulation and communicate their contact details on their public website or directly to CONTROLLER. d. Use of other processors of personal data The Processor may not retain the services of other processors of personal data without CONTROLLER’s prior written permission. The Processor shall notify CONTROLLER in advance in writing of any planning changes concerning the adding or replacement of other processors of personal data, in which case CONTROLLER may, for a well-founded reason, deny the change. The Processor is responsible for ensuring that a proper contract that meets the obligations posed by data protection legislation has been concluded between the Processor and the other processor of personal data. e. Processor’s obligation to assist and provide information The Processor shall assist CONTROLLER in fulfilling its obligation to respond to requests that concern the exercise of the data subject's rights pursuant to data protection legislation and in ensuring that the obligations set forth in Articles 32 through 36 of the Data Protection Regulation are complied with. Among other things, the Processor shall assist CONTROLLER in making the notifications required under Articles 33 and 34 of the Data Protection Regulation to the supervisory authority and the data subject within the time period specified in the Data Protection Regulation. The Processor shall also, on request, cooperate with the supervisory authority as provided under Article 31 in the performance of its tasks. 34 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 The Processor shall provide CONTROLLER with all the information that is necessary for proving compliance with the obligations imposed by data protection legislation. The Processor shall constantly maintain the said information and assess the adequacy of the actions. The Processor shall, on its own initiative, communicate to CONTROLLER the places where the processing of personal data takes place and any changes to them if they are not clearly stated in the Agreement or in the documentation available to CONTROLLER. The Processor shall fulfil its obligation to assist and provide information under this subparagraph 6.5 without any separate compensation. f. Processing of personal data abroad The Processor may not process the personal data included in CONTROLLER’s material in any other way than stated in the Agreement or in annexes that are ranked higher in the order of precendence than this annex, in respect of GDPR. Unless otherwise expressly stated in the Agreement or in annexes that are ranked higher in the order of precedence than this annex, the Processor may not process the personal data included in CONTROLLER’s material outside of the European Economic Area (EEA). If, according to the Agreement or an annex that is ranked higher in the order of precedence than this annex, the Processor is allowed to process the personal data included in CONTROLLER’s material outside of the EEA, the Processor shall notify CONTROLLER of the commencement of such processing of personal data in writing no later than 30 days before the planned commencement date. If the Processor processes personal data in any county other than those listed as trusted countries by the EU Commission, the Processor undertakes to conclude a separate contract on the processing of personal data with CONTROLLER in accordance with the EU model clauses before the processing of personal data is commenced. In the event that an agreement based on the EU model clauses would not, at a later date, be considered as a sufficient means of compliance with the requirements of data protection legislation, the Processor commits to regularising, without delay, the processing of personal data together with CONTROLLER. The Processor undertakes to transfer the processing of personal data to the EEA or to a trusted country without undue delay if the processing country is removed from the list of trusted countries. CONTROLLER may not incur any additional costs as a result of the transfer. The Processor shall guarantee the same level of information security and data protection irrespective of the country where the personal data are processed. g. Damages If the Processor has acted in contravention with the Data Protection Regulation as a result of which CONTROLLER or a data subject has incurred material or immaterial loss or damage, the Processor shall be liable to compensate such loss or damage. If an administrative fine referred to in Article 83 of the Data Protection Regulation is imposed on CONTROLLER and the fine is proven to be attributable to an act or omission of the Processor or its subcontractor or an individual in their employ, the Processor shall be liable to compensate the euro amount of the administrative fine to CONTROLLER in full irrespective of any limitation of liability potentially included in the Agreement. 6. Processor’s obligations to notify and report a. Obligation to notify The Processor shall, without undue delay, notify CONTROLLER of any circumstances that have come to the Processor’s attention that may have an effect on the information security related to the subject of the Agreement and of the measures and any consequences resulting from them. The obligation concerns, among other things, information security risks, changes to security arrangements, actual or attempted information security violations, unpatched system vulnerabilities, denial-of-service attacks and other similar nonconformances that are likely increase the risk posed to the confidentiality, integrity and availability of CONTROLLER’s material. The Processor shall inform CONTROLLER of a responsible person to provide further information. If the circumstance in question is related to personal data, the Processor shall notify CONTROLLER of the related data subject groups and the estimated numbers. 35 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 b. Periodic reporting The Processor shall monitor the attainment of the level of information security specified in the Agreement on a regular basis and in a systematic manner. The Processor shall record any nonconformances and report them without delay and initiate corrective actions as soon as possible. 7. Actions in the event of an information security breach The Processor shall have in place written instructions on how to act in the event of information security breaches. TheCONTROLLER shall be liable to assist Processor in minimising the damage related to data security breaches and in clarifying the matter with the authorities. 8. Other terms and conditions a. Preparation of descriptions and statements CONTROLLER shall be responsible for the preparation of a personal data file description, privacy statement, description of processing operations, impact assessment and information system description and for the implementation of prior consultation. The Processor shall provide CONTROLLER with the information needed in preparing and implementing the above without any separate compensation according to the GDPR. b. Amendments to the Agreement due to reasons related to information security or data protection and additional work If recommendations, guidelines or regulations related to the legislation on information security or data protection or its interpretation change, the Contracting Parties shall make the necessary amendments to the Agreement. has the right to order a necessary amount of additional work from the Processor in order to implement the amendments to the Agreement or to HUS's guidelines on the processing of personal data. 36 / 37 Restricted diffusion 2020_00105 TARID Consortium Agreement, v. 4 June 25, 2020 37 / 37 Restricted diffusion Tartu ülikooli eesmärgid TARID projektis 1.09.2020 – 30.08.2023 Vastutav täitja Pärt Peterson, PhD, molekulaarimmunoloogia professor, Bio- ja siirdemeditsiini instituut, Tartu ülikool. Email: [email protected] TARID projekti laiem eesmärk on leida vastust - miks tekivad organismis autoimmuunsed reaktsioonid, kui tüümuses ei toimi üks olulisemaid immuuntolerantsust reguleerivaid geene, Autoimmuunne Regulaator (AIRE)? Kas neid vigu on võimalik ravilahendustega parandada? AIRE geeni vea korral hakkab organismi immuunsüsteem ründama iseennast. Teisisõnu tekib autoimmuunne reaktsioon. Põhjuseks on, et tüümusest ei eemaldata autoreaktiivseid T rakke; need reageerivad inimese enda antigeenidega, hävitatavad organismi kudesid ning haiguse 1. tüüpi autoimmuunne polüendokrinopaatia sündroom tagajärjel tekivad patsientidel mitmed autoimmuunsed haigused, mille mehhanismid on ebaselged. Lisaks on AIRE geeni puudus seotud müasteeniaga, mis seotud tümoomiga, tüümuse epiteeli kasvajaga. Kuna mehhanistliku tausta selgitamine otse inimeses on praktiliselt võimatu, siis on AIRE geeni ja seotud haiguste põhjuste selgitamiseks välja töötatud AIRE-puuduliku looma mudel rotis, kelles tekib inimesega sarnane haigussündroom. Inimese haigust peegeldava katseloomamudeli olemasolu võimaldab analüüsida immuunsüsteemi süvitsi, leida haiguse tagamaid ja loodetavasti testida ka võimalikke ravilahendusi. Tartu Ülikooli poolsed TARID projekti tegevused. Esimene projekti aasta 1.09. 2020 – 31.08. 2021. Esimene aasta keskendub tüümuse ja põrna rakkude eraldamisele ning transkriptoomilisele analüüsile AIRE-puudulikus ja terves rotimudelis. Et aru saada autoimmmuunsest reaktsioonist ja märklaudadest mida immuunsüsteem ründab, leiame mis on autoantigeenid antud loomades. Et mõista AIRE puuduliku geeni mõju tüümuses, loome tüümuse rakkude puhastamise meetodi, eraldame koostöös teiste projekti partneritega AIRE-puudulikust rotist kui katseloomast tüümuse rakud, määrame nende populatsioonide sagedused ja muutused. Seejärel teeme ülegenoomi transkriptoomi analüüsi, et määrata geenide ekspressiooni mutused. Saadud tulemusi võrdleme terve (ehk mitte geen-muudetud) katselooma geenide avaldumisega. Lisaks teeme üherakulise transkriptoomi analüüsi katselooma tüümusele ning põrnale kui sekundaarsele immuunkoele, kus toimub T rakkude aktivatsioon. Analüüsime saadud tulemusi bioinformaatiliselt. Teine projekti aasta 1.09. 2021 – 31.08. 2022. Teine aasta keskendub T ja B rakulise immuunrepertuaari määramisele AIRE-puudulikus ja terves rotimudelis. Et mõista autoimmuunset T ja B raku reaktsiooni, uurime loodud katseloomades T ja B raku repertuaari. Imetajate immuunrepertuaarid on väga suured (kuni 1012 erinevat klooni). Selleks et sellise mastaapse kloonide kogumi muutustest aru saada, töötame esmalt välja repertuaari analüüsi meetodi roti mudelile. Seejärel kui meetod toimib, eraldame rakud, neist RNA, ning kasutades uue põlvkonna sekveneerimist, teostame kloonide kogumi järjestuste määramise. Peale vastavat kloonide järjestuste annotatsiooni, analüüsime spetsiifilist repertuaari bioinformaatiliselt. Kolmas projekti aasta 1.09. 2022 – 31.08. 2023. Kolmas aasta keskendub võimalike ravilahenduste rakendamisele ja nende mõjude analüüsile. Antud osaprojektis teeme koostööd Nantes ülikooli teadlastega, kes on teinud märkimisväärseid jõupingutusi ravilahenduste välja töötamiseks. Oleme tihedas koostöös Nantes ülikooli ja teiste projekti osapooltega. Meie ülesanne on uurida, kuidas mõjutab anti- CD45RC vastase antikeha või madala doosiga interleukiin IL-2 ravi rakendamine Nantes ülikoolis kliinilist fenotüüpi kasutades AIRE-roti mudelit. Määrame selleks katseloomades autoantikehade olemasolu kui ka nende immuunrakkude (T ja B rakkude) repertuaarid ja analüüsime need bioinformaatiliselt. EUROOPA HARULDASTE HAIGUSTE VÕRGUSTIKU EJP RD 2019.A. TAOTLUSVOORU GRANDILEPING NR 3-4/1165-1 Eesti Vabariik, Sotsiaalministeeriumi kaudu, registrikood 70001952, asukoht Suur-Ameerika 1, 10122 Tallinn, keda esindab Sotsiaalministeeriumi põhimääruse § 9 punkti 9 alusel kantsler Marika Priske (edaspidi Ministeerium), Pärt Peterson (isikukood 36604182729) Tartu Ülikooli uurimisprojekti alusel (edaspidi Grandihoidja) ja Tartu Ülikool, registrikood 74001073, asukoht Ülikooli 18, 50090 Tartu, keda esindab Rektori käskkirja no. 19 (29.12.2017) alusel Taivo Raud (edaspidi Asutus), edaspidi koos Pooled ja eraldi Pool, Lähtudes EJP RD raamkonsortsiumi lepingust, mis allkirjastati ministeeriumi poolt 30. septembril 2019, Tartu Ülikooli uurimisprojektist TARID (edaspidi Projekt) ja Projekti konsortsiumleppest (edaspidi Konsortsiumileping) , mis allkirjastati Asutuse poolt 01.07.2020, sõlmisid käesoleva grandilepingu (edaspidi Leping) alljärgnevas: 1. LEPINGU ESE 1.1. Riigieelarveline toetus summas 75 000 (seitsekümmend viis tuhat) eurot (edaspidi toetus). 1.2. Asutus kasutab toetust EJP RD 2019. a. taotlusvooru ühiskonkursil osalenud ühisprojekti TARID „Thymic Abnormalities in Rare Immunological Diseases“, mille üks osa on Tartu Ülikooli uurimisprojekt, läbiviimiseks. Toetuse kasutamise täpsem kirjeldus on toodud Projektis (Lisa 4) . 1.3. Toetuse kasutamise periood on 01.09. 2020-31.08. 2023. 2. TOETUSE VÄLJAMAKSMISE AEG 2.1. Toetuse väljamakse aluseks on Projekt (Lisa 4) ja Konsortsiumileping (Lisa 5). 2.2. Ministeerium kannab toetuse Asutuse arveldusarvele vastavalt Asutuse koostatud eelarvele (Lisa 1) järgnevalt: 2.2.1. 25 000 eurot mitte hiljem, kui 14 päeva pärast Ministeeriumi poolt Lepingu jõustumisest teada saamist; 2.2.2. 25 000 eurot mitte hiljem, kui 14 päeva pärast I perioodi toetuse kasutamise aruande heakskiitmist Ministeeriumi poolt vastavalt punktile 3; 2.2.3. 25 000 eurot mitte hiljem, kui 14 päeva pärast II perioodi toetuse kasutamise aruande heakskiitmist Ministeeriumi poolt vastavalt punktile 3. 3. ARUANNETE ESITAMINE 3.1. Toetuse kasutamise aruandeperioodid on järgmised 3.1.1. I periood – 01.09.2020 – 31.08.2021 3.1.2. II periood – 01.09.2021 – 31.08.2022 3.1.3. III periood – 01.09.2022 – 31.08.2023 3.2. Grandihoidja esitab Ministeeriumile toetuse kasutamise aruande 20 (kahekümne) tööpäeva jooksul peale iga aruandeperioodi lõppemist. 3.3. Toetuse kasutamise aruanne esitatakse lepingu Lisas 3 toodud vormil. 4. POOLTE KOHUSTUSED 4.1. Ministeerium kohustub kandma eraldatud toetuse Lepingu punktis 1.2 nimetatud Projekti läbiviimiseks Lepingu punktis 2.2 toodud maksegraafiku aluses Asutuse arveldusarvele. 1 4.2. Asutus kohustub: 4.2.1. andma Ministeeriumi poolt ülekantud toetuse (v.a üldkululõivu ja töötasu) Grandihoidja käsutusse igasuguse viivituseta; 4.2.2. arvestama üldkululõivu proportsionaalselt antud Projekti raames läbiviidava teadustöö kuludega; 4.2.3. võimaldama Grandihoidjal ja tema poolt juhitaval uurimisrühmal kasutada Projekti täitmiseks oma infrastruktuuri; 4.2.4. vormistama Projekti töötajad (Lisa 2) tööle vastavalt töölepingu seaduses ettenähtud nõuetele ja määrama vastavalt Grandihoidja ettepanekule Projekti palgatud töötajatele töötasu, mille suurus on kooskõlas asutusesisese või asutusesisese võrdluse võimatuse korral Eesti keskmise palgatasemega vastavasisulise töö eest, võimaldama kraadiõppuritele stipendiumite maksmist Projektist; 4.2.5. sisestama Projekti andmed Eesti Teaduse Infosüsteemi (ETIS) ja avalikustama need ühe kuu jooksul pärast Lepingu allkirjastamist; 4.2.6. informeerima Ministeeriumi kõigist asjaoludest, mis takistavad Projekti täitmist antud Asutuses; 4.2.7. Ministeeriumi kirjalikul nõudel kandma neljateistkümne (14) päeva jooksul mitte- sihtotstarbeliselt kasutatud või Projekti lõpus kasutamata jäänud toetuse osa Ministeeriumi arveldusarvele; 4.2.8. võimaldama Ministeeriumil ja tema volitatud isikutel kontrollida Asutuse ja Grandihoidja esitatud aruannete õigsust, toetuse saamise tingimuseks olevate asjaolude paikapidavust ja toetuse kasutamise sihipärasust. 4.3. Grandihoidja kohustub: 4.3.1. kasutama talle eraldatud toetust heaperemehelikult, kokkulepitud korras ja tingimustel; 4.3.2. esitama Ministeeriumile saadud toetuse kasutamise kohta aruande iga perioodi kohta vastavalt Lepingu punktile 3. Aruande tähtajaks esitamata jätmise korral on Ministeeriumil õigus peatada toetuse ülekanne kuni aruande saabumiseni ja selle aktsepteerimiseni Ministeeriumi poolt; 4.3.3. Ministeeriumi kirjalikul nõudel esitama Lepingu punktis 3 toodud aruandlusperioodide kestel vahearuandeid kümne (10) tööpäeva jooksul vastavasisulise nõude saamisest; 4.3.4. Ministeeriumi kirjalikul nõudel esitama toetuse arvelt kulutuste tegemist tõendavate algdokumentide koopiad viie (5) tööpäeva jooksul vastavasisulise nõude saamisest; 4.3.5. arvestama Ministeeriumi poolt kirjalikult tehtud märkustega ja antud juhistega, juhistega mittenõustumisel (sh kui Grandihoidja leiab, et need ei ole kooskõlas Lepinguga) on Grandihoidjal õigus esitada kirjalik vastuväide; 4.3.6. viivitamatult teatama Ministeeriumile: 4.3.6.1. asjaoludest, mis takistavad Grandihoidjal Lepingu täitmist; 4.3.6.2. Lepingu Lisade muutmise vajalikkusest; 4.3.6.3. Lepingu täitmisel esinevatest muudest probleemidest; 4.3.7. nimetama Ministeeriumi ja Lepingu esemes kirjeldatud tegevuse toetajana kõigis asjakohastes trükistes (artiklid, raamatud, muud trükised jne) ja avalikel esinemistel, kasutades võimalusel Ministeeriumi logo vastavalt valitsusasutuste ühise visuaalse identiteedi stiilijuhistele ja EJP RD logo; 4.3.8.lõpetama Ministeeriumi või EJP RD soovil vastava sümboolika edasise kasutamise; 2 4.3.9. juhul, kui Projekti täitmisel korraldatakse inimuuringuid või loomkatseid, esitama Ministeeriumile inimuuringute eetikakomitee või loomkatsete läbiviimise loakomisjoni positiivse otsuse hiljemalt 10 (kümme) tööpäeva enne inimuuringute või loomkatsete algust. 5. VASTUTUS 5.1. Pooled täidavad oma kohustusi nõuetekohaselt, mõistlikult, heas usus, hoolsalt ning arvestades häid tavasid ja praktikat. 5.2. Pooled vastutavad oma kohustuste süülise mittetäitmise eest, kui täitmisest keeldumise õigus ei tulene Lepingust või seadusest. 5.3. Pool teatab teistele Pooltele Lepingu rikkumisest, kirjeldades rikkumist piisavalt täpselt kolmekümne (30) päeva jooksul arvates päevast, millal sai teada või pidi teada saama lepingu rikkumisest. 5.4. Lepingus sätestatud kohustuste mittetäitmise või mittenõuetekohase täitmise korral on Ministeeriumil õigus esitada toetuse saajale nõue rikkumise kõrvaldamiseks, andes Asutusele rikkumise kõrvaldamiseks mõistliku tähtaja. 5.5. Lepingu olulise rikkumise esinemisel, sh kui Asutus ei kõrvalda rikkumist selleks antud tähtaja jooksul või ei teata sama tähtaja jooksul rikkumist objektiivselt vabandavatest asjaoludest, on Ministeeriumil õigus Leping ühepoolselt erakorraliselt lõpetada, teavitades sellest vastava kirjaliku avaldusega Asutust. 5.6. Asutuse poolt Lepingust tulenevate kohustuste mittetäitmisel või mittenõuetekohasel täitmisel on Ministeeriumil õigus nõuda toetuse saajalt leppetrahvi tasumist kuni 10% (kümne protsendi) ulatuses toetusest ning vastavalt Ministeeriumi äranägemisele kogu toetuse või selle osa tagastamist. Asutus tagastab toetuse (või selle osa) ja tasub leppetrahvi 10 (kümne) tööpäeva jooksul arvates Ministeeriumi vastavasisulise nõude kättesaamisest. 5.7. Lepingust tulenevate kohustuste täitmata jätmise või mittekohase täitmisega teisele Poolele tekitatud otsese varalise kahju eest kannavad Pooled täielikku vastutust selle kahju täies ulatuses. 5.8. Lepingust tulenevate kohustuste mittetäitmist või mittenõuetekohast täitmist ei loeta Lepingu rikkumiseks, kui selle põhjuseks oli vääramatu jõud. Vääramatu jõuna käsitavad pooled võlaõigusseaduse § 103 lõikes 2 nimetatud asjaolusid. Pool, kelle tegevus lepingujärgsete kohustuste täitmisel on takistatud vääramatu jõu asjaolude tõttu, on kohustatud sellest kohe teisele poolele kirjalikku taasesitamist võimaldavas vormis teatama. Vääramatu jõu asjaolude ilmnemisel pikeneb Lepingu lõpptähtaeg nimetatud asjaolude esinemise perioodi võrra. Pool peab vääramatu jõu asjaolude äralangemisel asuma Lepingut täitma. Kui vääramatu jõu asjaolude tõttu on poole Lepingust tulenevate kohustuste täitmine takistatud enam kui 60 (kuuskümmend) kalendripäeva järjest, võib kumbki Pool Lepingu lõpetada. 5.9. Pooled ei vastuta kohustuste täitmata jätmise eest, kui Lepingu mittekohase täitmise põhjustab teine Pool oma Lepingust tulenevate kohustuste täitmata jätmisega. 6. VAIDLUSTE LAHENDAMINE 6.1. Lepingust tulenevad vaidlused lahendatakse eelkõige vastastikusel mõistmisel põhinevate ja avalikke huve arvestavate läbirääkimiste teel. 6.2. Kui läbirääkimised ei anna tulemusi, lahendatakse vaidlus Harju Maakohtus. 7. LEPINGU KEHTIVUS JA LEPINGUST TAGANEMINE 7.1. Leping jõustub hetkel, kui Lepingu pooled on sellele alla kirjutanud, ja kehtib, kuni pooled on kõik Lepingust tulenevad kohustused täitnud. 3 7.2. Pooltel on õigus Leping omavahelisel kirjalikul kokkuleppel igal ajal lõpetada. 7.3. Pooltel on õigus Lepingust ühepoolselt taganeda, teatades vastavast soovist teisele poolele vähemalt kolmkümmend (30) päeva ette. 7.4. Pool võib Lepingust taganeda, kui teine Pool on Lepingust tulenevat kohustust oluliselt rikkunud ning ei ole seda kõrvaldanud mõistliku tähtaja jooksul. 7.5. Lepingu lõpetamisel punktides 7.2-7.5 juhtudel tagastab Asutus kasutamata jäänud toetuse Ministeeriumile 10 (kümne) tööpäeva jooksul peale Lepingu lõppemist. 7.6. Lepingu lõppemine ei vabasta Pooli lepingu olemusest ja teise Poole huvist tulenevatest kohustustest. 8. Volitatud esindajad 8.1. Ministeeriumi esindajaks Lepingu täitmisega seotud küsimustes on: Mari Teesalu, tel. 626 9715, e-post [email protected], või teda asendav isik. 8.2. Asutuse esindajaks Lepingu täitmisega seotud küsimustes on: Grandihoidja Pärt Peterson, tel 53443855, e-posti aadress [email protected] 9. LEPINGU DOKUMENDID 9.1. Leping koosneb käesolevast Lepingust koos selle Lisadega ja pärast Lepingu sõlmimist sellest tehtud muudatustest, mis vormistatakse Lepingu lisana, mis on Lepingu lahutamatuteks osadeks ning moodustavad koos Lepinguga ühtse tervikliku Poolte vahel. 9.2. Lepingule on allkirjastamise hetkel lisatud alljärgnevad Lisad: 9.2.1. Lisa 1 – Projekti eelarve aastate kaupa 9.2.2. Lisa 2 – Projekti täitjate nimekiri; 9.2.3. Lisa 3 – Toetuse kasutamise aruande vorm; 9.2.4. Lisa 4 – Tartu Ülikooli uurimisprojekt TARID; 9.2.5. Lisa 5 – TARID projekti konsortsiumileping. 9.3. Lepingu osaks on lisaks käesolevatele Lepingule ja selle Lisadele muud kokkulepped, mis sõlmitakse Lepingu sõlmimise ajal või pärast Lepingu sõlmimist ning milles sätestatakse seosed Lepinguga. Pooled kinnitavad, et sellised kokkulepped moodustavad koos Lepinguga ühtse tervikliku kokkuleppe Poolte vahel. 10. LÕPPSÄTTED 10.1. Lepinguga reguleerimata küsimustes lähtuvad pooled Eesti Vabariigis kehtivatest õigusaktidest. 10.2. Leping on koostatud eesti keeles, elektroonselt ja allkirjastatud digitaalselt. 11. POOLTE REKVISIIDID JA ALLKIRJAD 11.1. Ministeerium: Sotsiaalministeerium Aadress: Suur-Ameerika 1, Tallinn Tel: 626 9301 Faks: 626 9209 E-post: [email protected] 11.2. Grandihoidja: Pärt Peterson Aadress: Ravila 19, Biomeedikum, Tartu Ülikool Tel: 53443855 E-post: [email protected] 4 11.3. Asutus: Tartu Ülikool Aadress: Lossi 3, 51003 Tartu Tel: 737 6193 E-post: [email protected] Arveldusarve: EE281010102000234007 /allkirjastatud digitaalselt/ /allkirjastatud digitaalselt/ /allkirjastatud digitaalselt/ 5 Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr 3-4/1165-1 Lisa 1 Pojekti eelarve aastate kaupa 01.09.2020 – 01.09.2021 – 01.09.2022 – Kogueelarve 31.08.2021 31.08.2022 31.08.2023 Töötasud ja sellega seotud 14 100 14 100 14 100 42 300 maksud (k.a stipendiumid) Põhivara - - - Lähetused 400 400 400 1200 Muud kulud (töömaterjalid 5500 5500 5500 16 500 ja alltöövõtt) Üldkululõiv 5000 5000 5000 15 000 Kokku 25 000 25 000 25 000 75 000 6 Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr 3-4/1165-1 Lisa 2 Projekti põhitäitjate ja projekti täitmisele kaasatud kraadiõppurite nimekiri. Perekonnanimi Eesnimi Ametikoht Koormus Kavandatud töötasu projektis (koos maksudega) või stipendium Peterson Pärt Professor 0.2 - Laan Martti Dotsent 0.2 - Sein Hanna Laborispetsialist 0.5 31,500 Stoljar Artur Doktorant 0.5 10,800 Kisand Kai Juhtivteadur 0.1 - Töötasu kokku 42,300 7 Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr 3-4/1165-1 Lisa 3 SOTSIAALMINISTEERIUM Suur-Ameerika 1 10122 Tallinn TOETUSE KASUTAMISE ARUANNE 20__. a kohta Asutus: Tartu Ülikool Grandihoidja: Pärt Peterson Projekti nimetus: Tartu Ülikooli projekt TARID Kulude aruanne: Kogueelarve Täitmine Täitmine projekti Täidetud kogu 20_ algusest eelarvest (%) Töötasud ja sellega seotud maksud (k.a stipendiumid) Põhivara Lähetused Muud kulud (töömaterjalid ja alltöövõtt) Üldkululõiv Kokku 20__. a tegevuste kirjeldus (vähemalt 4000 tähemärki): ______________________________ _________________________________________ Grandihoidja (allkiri, kuupäev) Asutuse esindaja (nimi, allkiri, kuupäev) 8
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel